ACUMEN PHARMACEUTICALS INC (ABOS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ABOS • US00509G2093

2.56 USD
+0.09 (+3.64%)
At close: Feb 11, 2026
2.53 USD
-0.03 (-1.17%)
After Hours: 2/11/2026, 6:20:41 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

ABOS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. ABOS has a bad profitability rating. Also its financial health evaluation is rather negative. ABOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ABOS has reported negative net income.
  • ABOS had a negative operating cash flow in the past year.
  • ABOS had negative earnings in each of the past 5 years.
  • In the past 5 years ABOS always reported negative operating cash flow.
ABOS Yearly Net Income VS EBIT VS OCF VS FCFABOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • ABOS has a worse Return On Assets (-93.76%) than 73.61% of its industry peers.
  • ABOS has a Return On Equity of -143.12%. This is in the lower half of the industry: ABOS underperforms 62.72% of its industry peers.
Industry RankSector Rank
ROA -93.76%
ROE -143.12%
ROIC N/A
ROA(3y)-27.08%
ROA(5y)-28.29%
ROE(3y)-32.76%
ROE(5y)-32.44%
ROIC(3y)N/A
ROIC(5y)N/A
ABOS Yearly ROA, ROE, ROICABOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • ABOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABOS Yearly Profit, Operating, Gross MarginsABOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ABOS has more shares outstanding
  • Compared to 5 years ago, ABOS has more shares outstanding
  • The debt/assets ratio for ABOS is higher compared to a year ago.
ABOS Yearly Shares OutstandingABOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABOS Yearly Total Debt VS Total AssetsABOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ABOS has an Altman-Z score of -4.59. This is a bad value and indicates that ABOS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ABOS (-4.59) is comparable to the rest of the industry.
  • ABOS has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • ABOS's Debt to Equity ratio of 0.29 is on the low side compared to the rest of the industry. ABOS is outperformed by 67.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -4.59
ROIC/WACCN/A
WACCN/A
ABOS Yearly LT Debt VS Equity VS FCFABOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • ABOS has a Current Ratio of 6.02. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ABOS (6.02) is better than 62.91% of its industry peers.
  • ABOS has a Quick Ratio of 6.02. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
  • ABOS has a Quick ratio of 6.02. This is in the better half of the industry: ABOS outperforms 64.44% of its industry peers.
Industry RankSector Rank
Current Ratio 6.02
Quick Ratio 6.02
ABOS Yearly Current Assets VS Current LiabilitesABOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • ABOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.04%.
EPS 1Y (TTM)-62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -3.90% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-22.12%
EPS Next 2Y0.88%
EPS Next 3Y4.2%
EPS Next 5Y-3.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABOS Yearly Revenue VS EstimatesABOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2030 2031 2032 2033 50M 100M 150M 200M 250M
ABOS Yearly EPS VS EstimatesABOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABOS. In the last year negative earnings were reported.
  • Also next year ABOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABOS Price Earnings VS Forward Price EarningsABOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABOS Per share dataABOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.88%
EPS Next 3Y4.2%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ABOS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (2/11/2026, 6:20:41 PM)

After market: 2.53 -0.03 (-1.17%)

2.56

+0.09 (+3.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners63.32%
Inst Owner Change-0.22%
Ins Owners1.61%
Ins Owner Change11.99%
Market Cap155.06M
Revenue(TTM)N/A
Net Income(TTM)-133.35M
Analysts88.33
Price Target7.14 (178.91%)
Short Float %1.07%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.31%
Min EPS beat(2)-23.92%
Max EPS beat(2)28.53%
EPS beat(4)2
Avg EPS beat(4)1.76%
Min EPS beat(4)-26.63%
Max EPS beat(4)29.06%
EPS beat(8)3
Avg EPS beat(8)-5.77%
EPS beat(12)6
Avg EPS beat(12)-1.34%
EPS beat(16)6
Avg EPS beat(16)-15.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.38%
PT rev (3m)-17.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.98%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)10.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -93.76%
ROE -143.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.08%
ROA(5y)-28.29%
ROE(3y)-32.76%
ROE(5y)-32.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -352%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.02
Quick Ratio 6.02
Altman-Z -4.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)197.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
EPS Next Y-22.12%
EPS Next 2Y0.88%
EPS Next 3Y4.2%
EPS Next 5Y-3.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.58%
EBIT Next 3Y653.25%
EBIT Next 5YN/A
FCF growth 1Y-169.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-169.11%
OCF growth 3YN/A
OCF growth 5YN/A

ACUMEN PHARMACEUTICALS INC / ABOS FAQ

What is the fundamental rating for ABOS stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABOS.


What is the valuation status of ACUMEN PHARMACEUTICALS INC (ABOS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACUMEN PHARMACEUTICALS INC (ABOS). This can be considered as Overvalued.


What is the profitability of ABOS stock?

ACUMEN PHARMACEUTICALS INC (ABOS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ACUMEN PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ACUMEN PHARMACEUTICALS INC (ABOS) is expected to decline by -22.12% in the next year.